Erasca, Inc.
NASDAQ:ERASBiotechnology
-$0.02 today
- Market cap
- $4.83B
- Beta
- 0.73
- P/E (TTM)
- -15.3
- EPS (TTM)
- -$0.91
Volume 8.94M
Average 6.79M
ERAS Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Erasca, Inc.NASDAQ: ERAS
Cost of Revenue · Q3 FY2026 · quarter ended Sep 2026
Cost of revenue remains negative
Q3 FY2026 cost of revenue was $0, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $1.47M. Over 3 fiscal years it compounded at +5.6% a year.
Context
- Cost of revenue increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly cost of revenue holds near $0 or moves back toward the trailing-twelve-month quarterly average of $366.5K.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 3.11M USD
- Year-over-year change
- —
- 4-year CAGR
- +39.1%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.11M | — |
| FY2024 | 2024-12-31 | 0 | -100.0% |
| FY2023 | 2023-12-31 | 3.73M | +41.3% |
| FY2022 | 2022-12-31 | 2.64M | +218.6% |
| FY2021 | 2021-12-31 | 829K | — |
Cost of Revenue vs competitors
How ERAS compares with its peers on the latest reported figures
- ERAS's LTM Sep 2026 cost of revenue of $1.47M is the 6th highest of the 9 companies compared; the peer median is $5.94M.
- Its year-over-year change of +76.2% is the 3rd highest of 6, against a peer median of +50.7%.
- Over three fiscal years its annual growth of +5.6% compares with a peer median of +29.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $244.96M | +232.7% | +29.8% | 108.7% | |
| LTM Jun 2026 | $10.3M | -1.0% | — | 6.1% | |
| LTM Jun 2026 | $9.24M | — | — | — | |
| LTM Mar 2026 | $8.06M | — | — | 16.3% | |
| LTM Mar 2026 | $3.83M | +1795.5% | — | 5.3% | |
| LTM Sep 2026 | $1.47M | +76.2% | +5.6% | — | |
| LTM Sep 2026 | $942K | +50.7% | — | — | |
| LTM Mar 2026 | $320K | +5.3% | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding ERAS) | $5.94M | +50.7% | +29.8% | 11.2% | |
Competitors are the stored peer set for ERAS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 829K | 2.64M | 3.73M | 0 | 3.11M |
| Gross Profit | (829K) | (2.64M) | (3.73M) | 0 | (3.11M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 73.92M | 112.46M | 103.82M | 115.36M | 92.85M |
| Selling, General & Admin | 22.62M | 32.99M | 37.7M | 41.73M | 38.55M |
| Operating Expenses | 124.05M | 244.81M | 137.79M | 179.59M | 128.3M |
| Depreciation & Amortization | 829K | 2.64M | 3.73M | 3.81M | 3.11M |
| EBITDA | (121.94M) | (240.16M) | (121.31M) | (153.28M) | (121.44M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (124.88M) | (247.45M) | (141.53M) | (179.59M) | (131.41M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 190K | 4.9M | 16.71M | 20.09M | 16.61M |
| Interest Expense | 0 | 201.36M | 0 | 0 | 0 |
| Other Income / Expenses | 2.12M | 4.65M | 16.48M | 17.94M | 6.86M |
| Income Before Tax | (122.76M) | (242.81M) | (125.04M) | (161.65M) | (124.55M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (122.76M) | (242.81M) | (125.04M) | (161.65M) | (124.55M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.03) | (1.99) | (0.83) | (0.69) | (0.44) |
| EPS (Diluted) | (1.03) | (1.99) | (0.83) | (0.69) | (0.44) |
| Weighted Avg Shares | 119.1M | 122.02M | 150.18M | 233.82M | 283.53M |
| Weighted Avg Shares (Diluted) | 119.1M | 122.02M | 150.18M | 233.82M | 283.53M |
Erasca, Inc.
NASDAQ:ERAS
Intrinsic Alpha fair value
Locked
Current Price
$13.76
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.